In the midst of the current Ebola outbreak, there has been much made of the role of big pharma in the race to stem the tide of the deadly virus. Many commentators, non-governmental organizations and governments have been critical of drug companies in the past and currently for what is seen as their lack of interest in developing vaccines and cures for illnesses that are deadly, but just not profitable.
But numbers are numbers, and the decision-makers of publicly-traded companies are obligated to conduct their business in a way that returns an acceptable return on investment to shareholders.
In an editorial for Forbes (more…)